Fresenius Invests to Help Humacyte Develop Implantable Blood Vessels

Fresenius has invested an additional $25 million in Humacyte Inc, to help the implantable vessel company get market approval. The new vessels, which can be used to create and repair vascular accesses, are now being tested in a clinical trial for use in dialysis.

Read the full article » | Posted 09-14-2021

Related Articles

• Outset Halts Tablo Sales for Home Use Pending FDA Review of New Features Posted 07-13-2022
• Baxter Showcases Kidney Care Products Posted 06-10-2022
• DaVita and Medtronic to Launch New Kidney Tech Company Posted 06-10-2022
• Outset Tablo Could Boost Use of Home Hemodialysis Posted 05-12-2022